Elmiron
Pajjiż: Awstralja
Lingwa: Ingliż
Sors: Department of Health (Therapeutic Goods Administration)
Fuljett ta 'informazzjoni
(PIL)
31-05-2024
Karatteristiċi tal-prodott
(SPC)
31-05-2024
Ingredjent attiv:
Pentosan polysulfate sodium
Disponibbli minn:
Arthropharm Pty Ltd
Klassi:
Medicine Registered
Fuljett ta 'informazzjoni
CONSUMER PRODUCT INFORMATION
ELMIRON has been used by some people for up to five years
continuously
without significant unwanted effects.
If your bladder condition or symptoms become worse, you should
consult
your doctor immediately and
STOP taking ELMIRON.
Some people may experience mild effects of swelling, headache,
dizziness, nausea, indigestion, or diarrhoea. If any of these
occur and are
bothersome, contact your doctor. Other unwanted effects not listed
may
also occur in some patients. Tell your doctor if you notice any other
effects.
If you accidentally take too many capsules, you should contact your
doctor. There are no known instances of people suffering damage
from
taking too much ELMIRON.
This is not all the information that is available on ELMIRON, If you
have any
more questions or are not sure about anything, ask your doctor or
pharmacist.
ELMIRON is supplied in white opaque hard gelatin capsules, each
capsule containing 100 mg pentosan polysulphate sodium (the active
drug), microcrystalline cellulose and magnesium stearate. It is
formulated
for oral use.
The Australian Register Number is AUST R 48446.
ELMIRON is an oral treatment for interstitial cystitis otherwise known
as a
chronic inflammation of the bladder wall. ELMIRON is passed by the
kidneys into the urine, where it coats the damaged bladder
wall. This
improves the bladder’s protective lining. After taking ELMIRON, it
may be
at least six to eight weeks before you notice improvement in your
symptoms.
ARTHROPHARM PTY LTD IS COMMITTED TO THE BETTER HEALTH OF
ALL AUSTRALIANS.
CONSUMER PRODUCT INFORMATION IS PART OF THIS COMMITMENT.
ARTHROPHARM PTY LIMITED
111 Bronte Road, Bondi Junction NSW 2022
February 1994
Keep ELMIRON out of the reach of children.
•
Keep the capsules away from sunlight and away from the damp
•
and store in a cool place. Therefore, do not store
ELMIRON in the
bathroom or near the kitchen sink.
Keep ELMIRON in the bottle given to you by you
Aqra d-dokument sħiħ
Karatteristiċi tal-prodott
®
ELMIR
ON
CA
PSULES – 100 MG
(pentosan polysulpha
te sodium)
DESCR
IPTION
Pentosan
polysulpha
te
sodium
is
a
semi-synthetically
pr
oduced
hepar
in-lik
e
macr
omolecular
carbo
-
hydra
te
der
iv
a
tiv
e
w
hich
chemically
and
str
ucturally
resembles
glycosaminoglycans
. It
is
a
w
hite
odour
less
po
wder
, slightly
hydr
oscopic
and
soluble
in
w
a
ter
to
50%
a
t pH
6.
It
has
a
molecular
w
eight
of 4000 to 6000 Dalton.
ELMIRON
is
supplied
in
w
hite
opaque
har
d
gela
tin
ca
psules
containing
100
mg
pentosan
polysul
pha
te
sodium,
micr
ocr
ys
talline cellulose,
and magnesium s
teara
te.
It is f
or
m
ula
ted f
or oral use.
PHAR
MACOLOGY
ELMIRON
inhibits
the
for
ma
tion
of
activ
a
ted
factor
Xa
resulting
in
limited
anti-coagulant
activity
(a
bout
1/15 tha
t of hepar
in).
It mobilises plasminogen activ
a
tor (tP
A),
accounting f
or its fibr
inolytic activity
.
It
media
tes
the
release,
fr
om
endothelial
cells
and
the
liv
er
, of
lipopr
otein
lipases
w
hich
split
triglycer
ides
into
free
fa
tty
acids
and
glycer
ol
pr
o
viding
a
lipolytic
ef
fect.
In
animal
exper
iments
, ELMIRON
has
been
sho
wn to hav
e an anti-inflamma
tor
y ef
fect.
In
the
ra
bbit
bladder
, ELMIRON
has
been
repor
ted
to
pr
o
vide
an
anti-adher
ence
ef
fect
ag
ains
t
infectious micr
o-or
g
anisms ther
eb
y pr
e
venting ur
inar
y infection.
It
has
been
sugges
ted,
tha
t in
pa
tients
with
inter
stitial
cys
titis
, the
bladder
has
ar
eas
w
hich
ar
e
den
uded
of
the
pr
otectiv
e
glycosaminoglycans
lay
er
. Ther
ef
or
e,
a
pr
oposed
mechanism
of
action
of
ELMIRON
in
this
disease
is
tha
t it
binds
to
the
transitional
epithelium
of
the
bladder
and
coa
ts
the
den
uded
ar
eas
.
ELMIRO
N
b
in
d
s w
a
te
r v
e
ry
str
o
ng
ly
Aqra d-dokument sħiħ
